3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma
3
Leukemia, Myeloid, Acute
3
Lymphoma, B-Cell
2
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Neuroblastoma
1
Myelodysplastic Syndromes
1
Lymphoproliferative Disorders
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Immunoblastic Lymphadenopathy
1
Enteropathy-Associated T-Cell Lymphoma
1
Interventions
Rituximab
25
Lenalidomide
21
Cyclophosphamide
20
Prednisone
14
obinutuzumab
12
Vincristine
12
Doxorubicin
11
Magnetic Resonance Spectroscopy
10
Bendamustine Hydrochloride
9
Specimen Handling
8
ibrutinib
7
Biopsy
7
fludarabine
6
pembrolizumab
5
fludarabine phosphate
5
Radiotherapy
5
Peripheral Blood Stem Cell Transplantation
5
zanubrutinib
4
venetoclax
4
tazemetostat
4
Whole-Body Irradiation
4
R-CHOP protocol
4
Prednisolone
3
Mycophenolic Acid
3
Etoposide
3
Cyclosporine
3
tisagenlecleucel
2
polatuzumab vedotin
2
orelabrutinib
2
loncastuximab tesirine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Follicular
×
etoposide phosphate
×
90 days
×
Clear all
NCT04663347
2026-06-02
EPCOREâ„¢ NHL-2
Genmab
Phase 1/2
Active not recruiting
543 enrolled